New 'Smart Bomb' drug targets Hard-to-Treat cancers in first human trial
NCT ID NCT07085091
First seen Nov 01, 2025
Summary
This early-stage study is testing a new drug called ALX2004 in people with advanced lung, head and neck, esophageal, or colorectal cancers that have not responded to standard treatments. ALX2004 is an antibody-drug conjugate designed to deliver a cancer-killing payload directly to cells that have a protein called EGFR on their surface. The trial will first find a safe dose and then check for signs that the drug can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ALX Center 1
RECRUITINGSpokane, Washington, 99208, United States
-
ALX Center 2
RECRUITINGFairfax, Virginia, 22031, United States
-
ALX Center 3
RECRUITINGGrand Rapids, Michigan, 49546, United States
-
ALX Center 4
RECRUITINGWest Valley City, Utah, 84119, United States
-
ALX Center 5
RECRUITINGHouston, Texas, 77030, United States
-
ALX Center 6
RECRUITINGPortland, Oregon, 97213, United States
-
ALX Center 7
RECRUITINGTampa, Florida, 33612, United States
-
ALX Center 8
RECRUITINGFarmington Hills, Michigan, 48334, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ALX2004 (an antibody-drug conjugate that targets EGFR on cancer cells)
What this could lead to
If this works, it could point toward a new treatment option for people with advanced lung, head and neck, esophageal, or colorectal cancers that have stopped responding to other therapies.
What could go wrong
This is a very early (Phase 1) trial, so the main goal is safety, not effectiveness. The drug may not shrink tumors, and side effects could be significant. Only a small number of people will receive the potentially effective dose.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.